XSHE
002172
Market cap647mUSD
Oct 09, Last price
5.91CNY
1D
4.42%
1Q
98.99%
Jan 2017
-42.23%
IPO
-51.76%
Name
Jiangsu Aoyang Health Industry Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Aoyang Health Industry Co.ltd. is a multifaceted enterprise primarily engaged in two key sectors: chemical fiber manufacturing and healthcare services. Globally, the company manufactures and distributes a range of chemical fibers, including advanced functional fibers and traditional viscose varieties. Complementing its industrial activities, Aoyang Health maintains a significant presence in the health sector. This includes the operation of hospitals, rehabilitation facilities, and retail pharmaceutical outlets. Furthermore, its healthcare portfolio extends to offering comprehensive health management solutions, managing pharmaceutical logistics, and distributing medical products. Established in 2001 and headquartered in Zhangjiagang, China, the entity underwent a name change in September 2018, transitioning from its previous designation, Jiangsu Aoyang Technology Corporation Limited, to its current identity.
Key people
Jing Li
General Manager · since 2025
Xiao Wang
Chief Financial Officer, Deputy General Manager · since 2025
Wei Wang
Deputy General Manager · since 2020
Zhihao Zhu
Deputy General Manager · since 2025
Chao Ji
Secretary of the Board, Director · since 2019
Yan Gao
Chairman of the Board · since 2025
Ping Lu
Director · since 2025
Vice Chairman of the Board · since 2025
Ye Shen
Deputy General Manager, Staff Elected Director · since 2025
Guoping Xi
Director · since 2025
Tingting Ni
Independent Director · since 2025
Zhuoya Sun
Independent Director · since 2025
Xiaojun Wu
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||